Factors influencing the surface modification of mesenchymal stem cells with fluorescein-pegylated lipids

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 11, 2013, Pages 1731-1738

  Takafuji, Yoshimasa ^a   Higuchi, Yuriko ^a,b   Muro, Atsushi ^a   Oshiro, Kohei ^a   Kawakami, Shigeru ^a,b   Yamashita, Fumiyoshi ^a   Hashida, Mitsuru ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Cell surface modification; Cell therapy; Mesenchymal stem cell; Pegylated lipid

Indexed keywords

LIPID; MACROGOL; PEGYLATED LIPID; UNCLASSIFIED DRUG;

ADHERENT CELL; ARTICLE; CELL MEMBRANE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EXPOSURE; HUMAN; HUMAN CELL; LIPID COMPOSITION; MESENCHYMAL STEM CELL; MOLECULAR WEIGHT; TEMPERATURE;

CELL LINE; CELL SURVIVAL; FLUORESCEIN; HUMANS; MESENCHYMAL STROMAL CELLS; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; SURFACE PROPERTIES;

EID: 84888597728     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00291     Document Type: Article

References (30)

1. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med., 4, 328- 332 (1998).
2. Kuroyanagi Y, Yamada N, Yamashita R, Uchinuma E. Tissue-engineered product: allogeneic cultured dermal substitute composed of spongy collagen with fibroblasts. Artif. Organs, 25, 180-186 (2001).
3. Pellegrini G, Traverso CE, Franzi AT, Zingirian M, Cancedda R, De Luca M. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. Lancet, 349, 990- 993 (1997).
4. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: graft cell death and antideath strategies. J. Mol. Cell. Cardiol., 33, 907-921 (2001).
5. Kim SU, de Vellis J. Stem cell-based cell therapy in neurological diseases: A review. J. Neurosci. Res., 87, 2183-2200 (2009).
6. Shi RZ, Li Q. Improving outcome of transplanted mesenchymal stem cells for ischemic heart disease. Biochem. Biophys. Res. Commun., 376, 247-250 (2008).
7. Stephan MT, Irvine DJ. Enhancing cell therapies from the outside in: Cell surface engineering using synthetic nanomaterials. Nano Today, 6, 309-325 (2011).
8. Bhansali A, Upreti V, Khandelwal N, Marwaha N, Gupta V, Sachdeva N, Sharma RR, Saluja K, Dutta P, Walia R, Minz R, Bhadada S, Das S, Ramakrishnan S. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cells Dev., 18, 1407-1416 (2009).
9. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther., 9, 1647-1652 (2002).
10. Logan AC, Lutzko C, Kohn DB. Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr. Opin. Biotechnol., 13, 429-436 (2002).
11. Kato K, Itoh C, Yasukouchi T, Nagamune T. Rapid protein anchoring into the membranes of mammalian cells using oleyl chain and poly(ethylene glycol) derivatives. Biotechnol. Prog., 20, 897-904 (2004).
12. Ko IK, Kean TJ, Dennis JE. Targeting mesenchymal stem cells to activated endothelial cells. Biomaterials, 30, 3702-3710 (2009).
13. Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation. Bioconj. Chem., 16, 200-207 (2005).
14. Miura S, Teramura Y, Iwata H. Encapsulation of islets with ultrathin polyion complex membrane through poly(ethylene glycol)-phospholipids anchored to cell membrane. Biomaterials, 27, 5828- 5835 (2006).
15. Tomita U, Yamaguchi S, Sugimoto Y, Takamori S, Nagamune T. Poly(ethylene glycol)-lipid-conjugated antibodies enhance dendritic cell phagocytosis of apoptotic cancer cells. Pharmaceuticals (Ott.), 5, 405-416 (2012).
16. García-Gómez I, Elvira G, Zapata AG, Lamana ML, Ramírez M, García Castro J, García Arranz M, Vicente A, Bueren J, García-Olmo D. Mesenchymal stem cells: biological properties and clinical applications. Expert Opin. Biol. Ther., 10, 1453-1468 (2010).
17. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu. Rev. Biomed. Eng., 12, 87-117 (2010).
18. Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, Shao Y, Yang S, Han ZC. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: A pilot study. Front Med., 5, 94-100 (2011).
19. Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, Mendizabal AM, Pattany PM, Lopera GA, Fishman J, Zambrano JP, Heldman AW, Hare JM. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ. Res., 108, 792-796 (2011).
20. Lee PH, Kim JW, Bang OY, Ahn YH, Joo IS, Huh K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin. Pharmacol. Ther., 83, 723-730 (2008).
21. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet., 42, 419-436 (2003).
22. Busetto S, Trevisan E, Patriarca P, Menegazzi R. A single-step, sensitive flow cytofluorometric assay for the simultaneous assessment of membrane-bound and ingested Candida albicans in phagocytosing neutrophils. Cytometry A, 58A, 201-206 (2004).
23. Loike JD, Silverstein SC. A fluorescence quenching technique using trypan blue to differentiate between attached and ingested glutaraldehyde-fixed red blood cells in phagocytosing murine macrophages. J. Immunol. Methods, 57, 373-379 (1983).
24. Martin MM, Lindqvist L. The pH dependence of fluorescein fluorescence. J. Lumin., 10, 381-390 (1975).
25. Kenworthy AK, Nichols BJ, Remmert CL, Hendrix GM, Kumar M, Zimmerberg J, Lippincott-Schwartz J. Dynamics of putative raftassociated proteins at the cell surface. J. Cell Biol., 165, 735-746 (2004).
26. Yoshida M, Jo J, Tabata Y. Augmented anti-tumor effect of dendritic cells genetically engineered by interleukin-12 plasmid DNA. J. Biomater. Sci. Polym. Ed., 21, 659-675 (2010).
27. Lee KD, Nir S, Papahadjopoulos D. Quantitative analysis of liposome- cell interactions in vitro: Rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry, 32, 889-899 (1993).
28. Uster PS, Allen TM, Daniel BE, Mendez CJ, Newman MS, Zhu GZ. Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett., 386, 243-246 (1996).
29. Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett., 460, 129-143 (1999).
30. Botosoa EP, Maillasson M, Mougin-Degraef M, Remaud-Le Saëc P, Gestin JF, Jacques Y, Barbet J, Faivre-Chauvet A. Antibody-hapten recognition at the surface of functionalized liposomes studied by SPR: steric hindrance of pegylated phospholipids in stealth liposomes prepared for targeted radionuclide delivery. J. Drug Deliv., 2011, 368535 (2011).